Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Centrophenoxine (also known as meclofenoxate) has been investigated for its potential to support or treat symptoms of senility and age-related cognitive decline since the 1950s. Its use is primarily justified by scientific investigation rather than traditional use, as it was synthesized in the mid-20th century and has no roots in traditional medicine systems. Several animal studies suggest that centrophenoxine can improve learning and memory, potentially by increasing the synthesis of acetylcholine and enhancing neuronal metabolism. It also appears to have antioxidant properties and may reduce the accumulation of lipofuscin, a cellular waste product associated with aging in the brain. In humans, some small clinical trials from the 1970s and 1980s reported modest improvements in memory, alertness, and general cognitive function in elderly patients with age-related cognitive decline or mild dementia. However, these studies were generally limited by small sample sizes, short durations, and methodological weaknesses by modern standards. There are few, if any, large, high-quality randomized controlled trials supporting its use today, and it is not widely recognized as a first-line treatment for senility or dementia in current clinical practice. Nevertheless, the body of evidence, while limited and of variable quality, does provide some scientific basis for its use in this context, justifying a moderate but not strong evidence rating.

More about Centrophenoxine
More about Senility

Other ingredients used for Senility

Other health conditions supported by Centrophenoxine

Products containing Centrophenoxine